查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1136912

全球排卵障礙診斷市場-2022-2029

Global Ovulation Disorder Diagnosis Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

排卵障礙診斷市場的增長是由計劃懷孕增加、生育率下降以及公眾對各種排卵障礙認識的提高推動的

2 型糖尿病患者多囊卵巢綜合徵 (PCOS) 的患病率預計將推動市場增長

多囊卵巢綜合徵 (PCOS) 是一種常見的代謝和內分泌生殖疾病，與心血管、代謝和心理因素有關，據說影響全球約 7% 的女性。我來了。根據 2022 年 8 月發表在內分泌學前沿的一篇論文，糖尿病 (DM) 是一個全球公共衛生問題。到 2021 年，全球約有 5.37 億成年人（20-79 歲）將患有 DM，其中大多數是年輕人。現在越來越多的人在年輕時患上 2 型糖尿病（T2DM），而患有 T2DM 的女性在生育期更容易受到影響。 T2DM女性患者的生殖功能障礙正在謹慎增加。與非 T2DM 患者相比，T2DM 患者表現出更多的臨床變化，如月經紊亂和多囊卵巢。這可能與促黃體激素和胰島素協同作用引起的細胞內雄激素水平升高有關。

PCOS 還歸因於 2 型糖尿病患者的內在胰島素抵抗和高胰島素血症，這會刺激卵巢顆粒細胞促進小卵泡的生長和數量。 PCOS 和 T2DM 具有生化、臨床和代謝特徵。 PCOS 和 T2DM 患者之間的重疊率也很高。涉及 PCOS 的 T2DM 可導致對生殖系統的評估性損傷。 PCOS患者數量越多，市場就越大。

缺乏公眾意識會阻礙市場增長。

但是，醫療保健專業人員和患者之間的巨大知識差距是造成診斷延遲和治療變化多端的原因。此外，缺乏可獲取的循證信息讓受影響的女性感到沮喪。許多女性不知道排卵，導致誤診、不孕和相關的健康風險。

COVID-19 影響分析

COVID-19 的出現對全球排卵障礙診斷市場產生了相當大的影響。根據 2020 年 7 月發表在 BMC Medicine 上的一篇論文，多囊卵巢綜合徵 (PCOS) 是育齡女性最常見的內分泌疾病，患病率為 10-15%。甚至可能更多。因此，他們更有可能感染 COVID-19。另一方面，在大流行期間，交通限制和封鎖使許多患者難以接受常規治療。大流行期間許多行業被封鎖，這對市場產生了負面影響。

但是，在 2022 年年中而不是 2021 年，情況會有所改善，您將能夠在醫院接受治療。預計該市場在預測期內也將顯示出良好的增長。

全球排卵障礙診斷市場報告將提供對大約 65 多個市場數據表、65 多個圖表和 200 多頁（大約）的訪問。

內容

第一章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按排卵障礙劃分的市場細分
  • 按診斷劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 肥胖率上升
      • 糖尿病患病率增加
    • 約束因素
      • 診斷識別率低
    • 影響分析

第五章行業分析

  • 波特五力分析
  • 供應鏈分析
  • 監管分析
  • 定價分析
  • 未滿足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章排卵障礙

  • 多囊卵巢綜合徵
  • 高催乳素血症
  • 黃體期衰竭
  • 下丘腦功能障礙
  • 腫瘤
  • 自身免疫性卵巢炎
  • 原發性卵巢功能不全
  • 抵抗性卵巢綜合徵
  • 其他

第8章診斷

  • 荷爾蒙實驗室測試
  • 垂體和下丘腦的 CT 和 MRI 掃描
  • 卵巢活檢
  • 其他

第 9 章，最終用戶

  • 醫院
  • 婦科診所
  • 診斷中心
  • 其他

第 10 章按地區劃分

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 11 章競爭格局

  • 主要發展和戰略
  • 公司份額分析
  • 按治療類型劃分的基準

第 12 章公司簡介

  • 西門子醫療保健
    • 公司簡介
    • 治療類型組合和描述
    • 主要亮點
    • 財務摘要
  • GE Healthcare
  • Fujifilm Holdings
  • Swiss Precision Diagnostics
  • Toshiba Medical Systems Corporation
  • Carestream Health
  • Genova Diagnostics
  • Quest Diagnostics
  • LabCorp
  • Esaote

第 13 章全球排卵障礙診斷市場-DataM

簡介目錄
Product Code: DMCD803

Market Overview

Ovulation Disorder Diagnosis Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5.8% during the forecast period (2022-2029).

Ovulation disorders are the main source of infertility in women or girls. Ovulation disorders are disturbances in the production of an egg during a woman's menstrual cycle. The disorders often occur due to hypothalamic dysfunction, premature ovarian failure and polycystic ovary syndrome.

Market Dynamics

The ovulation disorder diagnosis market growth is driven by the rising adoption of planned pregnancies, a decrease in fertility rate along with increasing awareness of different ovulation disorders among the public

The prevalence of polycystic ovary syndrome (PCOS) in patients with type 2 diabetes is expected to drive the market growth

Polycystic ovary syndrome (PCOS) is a common metabolic and endocrine reproductive disease associated with cardiovascular, metabolic, and psychological factors affecting around 7% of women globally. As per the article published in Frontiers in Endocrinology in August 2022, Diabetes mellitus (DM) is a global public health concern. Around 537 million adults (20-79 years old) worldwide have developed DM in 2021, mostly in the younger age group. Now, more patients are developing type 2 DM (T2DM) at a younger age, and women with T2DM are affected more often during the reproductive period. Reproductive dysfunction in women patients with T2DM is cautiously increasing. Compared with patients without T2DM, patients with T2DM show more clinical changes, such as menstrual disorders and polycystic ovaries. This may be associated with the rise in cellular androgen levels induced by the cooperation of luteinizing hormone and insulin.

In addition, PCOS results from ovarian granulosa cells' stimulation by endogenous insulin resistance in type 2 diabetes and hyperinsulinem, which promote the growth and number of small follicles. PCOS and T2DM have biochemical, clinical, and metabolic characteristics. There is also a high overlap rate between patients with PCOS or T2DM. T2DM involved by PCOS may result in evaluative injuries to the reproductive system. The more patients with PCOS drive the market.

The lack of awareness in public will hamper the growth of the market

However, advanced knowledge gaps among health professionals and patients contribute to diagnostic delays and variation in care. In addition, a dearth of evidence-based, accessible information for affected women leads to dissatisfaction. Many women are unaware of ovulation, which disorders diagnosis information and causes infertility and is linked with various health risks.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global ovulation disorder diagnosis market. As per the article published in BMC Medicine in July 2020, in women of reproductive age, polycystic ovary syndrome (PCOS) constitutes the most frequent endocrine disorder, with a prevalence that may reach or even exceed 10-15%. The more chances are there of getting infected from COVID-19. On the other hand, many patients faced difficulty receiving their regular treatments during the pandemic due to transportation restrictions and lockdowns. Many industries are locked down in the pandemic, which negatively impacts the market.

However, because the situation is reversing in the middle of 2022 rather than 2021, the patient can now receive treatment in the hospital. The market will also show good growth in the forecast period.

Segment Analysis

The polycystic ovarian syndrome segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The polycystic ovarian syndrome segment is expected to boost the market over the period of the forecast. In some cases, a female doesn't make enough of the hormones required to ovulate. When ovulation doesn't happen, the ovaries develop many small cysts. These cysts generate hormones called androgens. Females with PCOS often have high levels of androgens. This results in more problems with a woman's menstrual cycle and can cause many symptoms of PCOS. If anyone has irregular periods and higher levels of androgen shown in blood tests, these women have PCOS. According to the Cleveland Clinic, PCOS is very common; up to 15% of women of reproductive age have it. Women not diagnosed and treated for PCOS may be at risk for developing conditions that raise the risk of cardiovascular disease, including obesity, high blood pressure, gestational diabetes, and high cholesterol. Therefore, diagnosing PCOS is important and increasing cases of PCOS lead to increasing demand for the diagnosis market. There's no single test specifically diagnosing polycystic ovary syndrome (PCOS). The healthcare professionals suggested a pelvic exam, blood tests, and ultrasound.

Geographical Analysis

North America region holds the largest market share of the global ovulation disorder diagnosis market

North America dominates the market for ovulation disorder diagnostics and is expected to show a similar trend over the forecast period. It is anticipated to hold a significant market size over the forecast period (2022-2029) owing to advanced healthcare infrastructure and rising awareness in public regarding ovulation disorder diagnosis. According to the Centers for Disease Control and Prevention, PCOS is one of the most common causes of female infertility, affecting 6% to 12% (as many as 5 million) of US women of reproductive age. The cases of PCOS and increasing health awareness in women drive the market in the North American region. In addition, the key players are adopting market strategies such as mergers and new launches of the product. For instance, in December 2021, Labcorp acquired the Toxikon Corporation, a contract research organization delivering best-in-class nonclinical testing services. Adding Toxikon to Labcorp Drug Development bolsters Labcorp's strong nonclinical development portfolio.

Competitive Landscape

The ovulation disorder diagnosis market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Siemens Healthcare, GE Healthcare, Fujifilm Holdings, Swiss Precision Diagnostics, Toshiba Medical Systems Corporation, Carestream Health, Genova Diagnostics, Quest Diagnostics, LabCorp, and Esaote, among others. The major players are adopting several growth strategies such as Treatment type launches, acquisitions, and collaborations, which are contributing to the growth of the ovulation disorder diagnosis market globally.

For instance,

  • In July 2022, Canon Medical Systems USA Inc. acquired NXC Imaging, a medical imaging equipment distributor and service provider headquartered in Minneapolis, Minnesota.

Toshiba Medical Systems Corporation (TMSC)

Overview:

TMSC is a company which is manufactured, sells, and provisions technical services for medical equipment, including diagnostic x-ray systems, medical x-ray CT systems, magnetic resonance imaging systems (MRI), computed tomography (CT) diagnostic ultrasound systems, radiation therapy systems, and others.

Treatment type Portfolio:

Computed Tomography: The system provides new clinical values such as functional diagnosis and dynamic observation apart from conventional morphological. Also able to provide 160 mm-wide coverage of 3D imaging in one rotation with 0.35 seconds, and it is patient-friendly medical care and requires less scanning time and exposure dose.

The global ovulation disorder diagnosis market report would provide access to approximately 65+ market data tables, 65+ figures, and in the range of 200+ (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet By Ovulation Disorders
  • 3.2. Market Snippet By Diagnosis
  • 3.3. Market Snippet By End-users
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rising obesity rates
      • 4.1.1.2. The increasing prevalence of diabetes
    • 4.1.2. Restraints:
      • 4.1.2.1. Lack of awareness of diagnosis
    • 4.1.3. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Regulatory Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Ovulation Disorders

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 7.1.2. Market Attractiveness Index, By Ovulation Disorders
  • 7.2. Polycystic Ovarian Syndrome*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Hyperprolactinemia
  • 7.4. Luteal Phase Defect
  • 7.5. Hypothalamus Dysfunction
  • 7.6. Tumors
  • 7.7. Autoimmune Oophoritis
  • 7.8. Primary Ovarian Failure
  • 7.9. Resistant Ovary Syndrome
  • 7.10. Others

8. By Diagnosis

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 8.1.2. Market Attractiveness Index, By Diagnosis
  • 8.2. Laboratory Testing of Hormones*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. CT Scan and MRI Scan of The Pituitary Gland and Hypothalamus
  • 8.4. Ovarian Biopsy
  • 8.5. Others

9. By End-users

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 9.1.2. Market Attractiveness Index, By End-users
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Gynecological Clinics
  • 9.4. Diagnostic Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.4.6.
    • 10.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.7.1. Brazil
      • 10.4.7.2. Argentina
      • 10.4.7.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Ovulation Disorders
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnosis
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-users

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Treatment type Benchmarking

12. Company Profiles

  • 12.1. Siemens Healthcare*
    • 12.1.1. Company Overview
    • 12.1.2. Treatment type Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. GE Healthcare
  • 12.3. Fujifilm Holdings
  • 12.4. Swiss Precision Diagnostics
  • 12.5. Toshiba Medical Systems Corporation
  • 12.6. Carestream Health
  • 12.7. Genova Diagnostics
  • 12.8. Quest Diagnostics
  • 12.9. LabCorp
  • 12.10. Esaote

LIST NOT EXHAUSTIVE

13. Global Ovulation Disorder Diagnosis Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us